Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pin Zhang

Showing results (321-330 of 373) with videos related to

Pageof 38
Sort By:
Ebiomedicine|May 18, 2019
Combination of apoptotic T cell induction and self-peptide administration for therapy of experimental autoimmune encephalomyelitisShimpei Kasagi, Dandan Wang, Pin Zhang, et al.
Blood|August 14, 2013
PARP-1 regulates expression of TGF-β receptors in T cellsPin Zhang, Hiroko Nakatsukasa, Eric Tu, et al.
Cancer Biology & Medicine|September 13, 2024
Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors: a retrospective study of HR+/HER2- advanced breast cancerQi Zhao, Mingxia Jiang, Jiaxuan Liu, et al.
Angewandte Chemie (International Ed. in English)|January 20, 2021
Chiral Spiro-Axis Induced Blue Thermally Activated Delayed Fluorescence Material for Efficient Circularly Polarized OLEDs with Low Efficiency Roll-OffYi-Pin Zhang, Xiao Liang, Xu-Feng Luo, et al.
Breast Cancer Research and Treatment|March 17, 2022
Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancerYun Wu, Yiqun Han, Qing Li, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|January 12, 2026
Factors associated with neoadjuvant therapy insensitivity and its prognostic impact in HER2-positive breast cancerYuhang Han, Bo Lan, Zexi Peng, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|January 8, 2013
[Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer]Wen-yue Ma, Pin Zhang, Bai-lin Zhang, et al.
Therapeutic Advances in Medical Oncology|January 5, 2026
Efficacy and safety of PARP inhibitors in metastatic breast cancer patients with homologous recombination repair pathway gene mutations: a retrospective multicenter real-world studyXuenan Peng, Ruixia Song, Ying Fan, et al.
Heliyon|October 10, 2024
The different sequences of CDK4/6 inhibitor and mTOR inhibitor in HR+/HER2-advanced breast cancer: A multicenter real-world studyYuqian Liao, Yujing Tan, Yipeng Li, et al.
Journal of Clinical Nursing|December 9, 2024
Prevalence of Frailty and Its Impact on Quality of Life in Older Patients With Breast Cancer: A Prospective Cross-Sectional StudyMin Xiao, Xi Chen, Lei Ji, et al.
Pageof 38

Showing results (321-330 of 373) with videos related to

Sort By:
Pageof 38
Ebiomedicine|May 18, 2019
Combination of apoptotic T cell induction and self-peptide administration for therapy of experimental autoimmune encephalomyelitisShimpei Kasagi, Dandan Wang, Pin Zhang, et al.
Blood|August 14, 2013
PARP-1 regulates expression of TGF-β receptors in T cellsPin Zhang, Hiroko Nakatsukasa, Eric Tu, et al.
Cancer Biology & Medicine|September 13, 2024
Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors: a retrospective study of HR+/HER2- advanced breast cancerQi Zhao, Mingxia Jiang, Jiaxuan Liu, et al.
Angewandte Chemie (International Ed. in English)|January 20, 2021
Chiral Spiro-Axis Induced Blue Thermally Activated Delayed Fluorescence Material for Efficient Circularly Polarized OLEDs with Low Efficiency Roll-OffYi-Pin Zhang, Xiao Liang, Xu-Feng Luo, et al.
Breast Cancer Research and Treatment|March 17, 2022
Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancerYun Wu, Yiqun Han, Qing Li, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|January 12, 2026
Factors associated with neoadjuvant therapy insensitivity and its prognostic impact in HER2-positive breast cancerYuhang Han, Bo Lan, Zexi Peng, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|January 8, 2013
[Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer]Wen-yue Ma, Pin Zhang, Bai-lin Zhang, et al.
Therapeutic Advances in Medical Oncology|January 5, 2026
Efficacy and safety of PARP inhibitors in metastatic breast cancer patients with homologous recombination repair pathway gene mutations: a retrospective multicenter real-world studyXuenan Peng, Ruixia Song, Ying Fan, et al.
Heliyon|October 10, 2024
The different sequences of CDK4/6 inhibitor and mTOR inhibitor in HR+/HER2-advanced breast cancer: A multicenter real-world studyYuqian Liao, Yujing Tan, Yipeng Li, et al.
Journal of Clinical Nursing|December 9, 2024
Prevalence of Frailty and Its Impact on Quality of Life in Older Patients With Breast Cancer: A Prospective Cross-Sectional StudyMin Xiao, Xi Chen, Lei Ji, et al.
Pageof 38